BMS Immunotherapy Strategic Update at JP Morgan Conference

[DK37]

From BMS's presentation at the big JP Morgan Healthcare conference going on right now, the major immunooncology drug company (Opdivo, Yervoy) mentioned prominently an interest in addressing "tougher tumors" like CRC and pancreatic.....

They then go into their very long second generation 2015-2016 trial start pipeline of which e.g. I am keep close eye on e.g. how the anti-CSF1R and anti-CD73 trials do (among others trials as well) as multiple attempts are being made to remove immunosupression from "cold" tumors like MSS-CRC.

http://seekingalpha.com/article/3805816 ... ipt?page=3

Quotes from their presentation this week:
"Beyond the combination of Yervoy and Opdivo, we are investigating novel mechanisms of action to be used in combination with Opdivo as a backbone agent. Our objective is to address the need of patients that do not respond to Opdivo, to patients that relapse after a response to Opdivo and obviously to seek signals in those tumors where the current signals are not strong,such as for example pancreatic and BROADLY COLORECTAL CANCER (emphasis added).

Beyond the focus on Opdivo and Yervoy, we are developing a really attractive pipeline of new agents, which are in early stage of development. I won’t go into a lot of detail on this slide but I’m actually very excited to have five agents in the clinic; anti-LAG3, Urelumab, anti-GITR, Lirilumab and the anti-CSF1R and to be adding three more agents in the clinic in 2016, the IDO, anti-CD73 and anti-OX40. So in 2016 we will have eight novel agents in the clinic and look forward to advancing every one of those programs."

-DK

[mariane]

Fingers crossed!

[JFrog]

You got to believe with this many "shots on goal" with good preclinical modeling that at least one of these will help the MSS mCRC community.